Press Release

Research Article cites AlbuVoid™ in Stem Cell Secretome Characterization

MONMOUTH JUNCTION, NJ, January 19, 2026 — Biotech Support Group (BSG) reports on its NRicher™-derived product, AlbuVoid™, for secretome analysis of a human induced pluripotent stem cell (hiPSC) -derived product to promote successful reproductive outcomes.

Research investigators at Gameto Inc, published an article entitled “Development of human induced pluripotent stem cell-derived ovarian support cells as a clinical-grade product for in vitro fertilization”, describing the analytical assessment required for the generation of a clinically suitable hiPSC-derived ovarian support cell (OSC) product.

Transcription Factor-mediated hiPSC differentiation generates OSCs that improve the in vitro maturation (IVM) of human oocytes. Quality, safety, and potency of raw material upgrades were assessed to establish the clinical readiness of the product Fertilo. For this purpose, a proteomic comparison of conditioned media of Research Use Only (RUO)-OSCs versus clinical grade (CG)-OSCs was performed. The article states “The conditioned media were subjected to consecutive centrifugations…to remove cellular remnants, and then passed through albumin depletion columns (AVK-50, AlbuVoid Albumin Depletion Columns Biotech Support Group) to eliminate HSA-derived albumin.”, prior to LCMS/MS analysis. The secretome analysis of both the RUO and CG lines revealed proteins associated with oocyte maturation and development competence, such as TGFB1, EGFR, and IGF2BP1/2/3, helping to confirm clinical grade process optimization.

The article concludes that the application of Fertilo in a longitudinal cohort analysis shows improvement in key outcomes, compared with traditional IVM. The findings demonstrate the first-time clinical development and application of an hiPSC-derived product to promote successful reproductive outcomes.

“Proteomic studies of cell secretomes have greatly increased in recent years. A major challenge however is analyzing the low abundance of the genuine secreted proteins, over the highly abundant proteins derived from the serum containing media, the preponderance of which is serum albumin. As demonstrated here, AlbuVoid™ is perfected suited to enrich the Albumin-depleted sub-proteome of cell secretomes.” stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

For more information visit: AlbuVoid™ at
https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

And AlbuVoid™ LC-MS On-Bead For Serum/Plasma Proteomics, at

https://www.biotechsupportgroup.com/AlbuVoid-LC-MS-On-Bead-For-Serum-Proteomics-p/avb-ms.htm

For more information on our complete line of Albumin & IgG Removal, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

For more information on NRicher™ for family=specific and targeted proteomics, visit:

https://www.biotechsupportgroup.com/category-s/340.htm

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: AlbuVoid™, Albumin depletion, human induced pluripotent stem cells (hiPSCs), cell secretome